GLTO

Galecto Inc

GLTO, USA

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

https://galecto.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GLTO
stock
GLTO

Published on: 2025-12-14 17:13:04 moha.gov.vn

Read more →
GLTO
stock
GLTO

Galecto (NASDAQ:GLTO) Price Target Raised to $36.00 at Guggenheim Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6

Analyst Picks

Strong Buy

1

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.37

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-47.00 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-29.18 %

Low 2%

High 10%

Debt to Equity

-

Medium

0.61

Low 1

High 0.3

Investors

* Institutions hold a combined 11.48% of the total shares of Galecto Inc

1.

Novo A/S

(7.5431%)

since

2025/06/30

2.

Renaissance Technologies Corp

(1.098%)

since

2025/06/30

3.

Susquehanna International Group, LLP

(1.0269%)

since

2025/06/30

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4413%)

since

2025/07/31

5.

Fidelity Extended Market Index

(0.3915%)

since

2025/07/31

6.

Fidelity Total Market Index

(0.1852%)

since

2025/07/31

7.

UBS Group AG

(0.1746%)

since

2025/06/30

8.

Fidelity Series Total Market Index

(0.1245%)

since

2025/07/31

9.

Bank of America Corp

(0.0927%)

since

2025/06/30

10.

NT Ext Equity Mkt Idx Fd - L

(0.0836%)

since

2025/06/30

11.

Northern Trust Extended Eq Market Idx

(0.0836%)

since

2025/06/30

12.

Tower Research Capital LLC

(0.0711%)

since

2025/06/30

13.

Vanguard U.S. Eq Idx £ Acc

(0.0257%)

since

2025/07/31

14.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0236%)

since

2025/06/30

15.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0199%)

since

2024/12/31

16.

NT Ext Equity Mkt Idx Fd - NL

(0.0195%)

since

2025/06/30

17.

Spartan Total Market Index Pool G

(0.0189%)

since

2025/07/31

18.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0151%)

since

2025/06/30

19.

BlackRock Inc

(0.0075%)

since

2025/06/30

20.

Barclays PLC

(0.0075%)

since

2025/06/30

21.

State St US Extended Mkt Indx NL Cl C

(0.0061%)

since

2025/08/31

22.

State St US Ttl Mkt Indx NL Cl A

(0.0057%)

since

2025/08/31

23.

Northern Trust Wilshire 5000

(0.0047%)

since

2025/06/30

24.

Spartan Extended Market Index Pool F

(0.0028%)

since

2025/07/31

25.

SSgA U.S. Total Market Index Strategy

(0.0026%)

since

2025/03/31

26.

SBI Securities Co Ltd

(0.0014%)

since

2025/06/30

27.

Fidelity U.S. Equity Index Ins Trust

(0.0005%)

since

2025/07/31

28.

Group One Trading, LP

(0%)

since

2025/06/30

30.

JPMorgan Chase & Co

(0%)

since

2025/03/31

31.

Squarepoint Ops LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-2.3609

EPS Estimate

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.